Ivermectin has been shown to inhibit nuclear import of host and viral proteins, limit infection by various RNA virus and this broad spectrum activity was also shown to prevail against the SARS-CoV-2 virus.
Ivermectin, a safe antiparasitic drug has been shown to possess wide anti-viral activity against a hose of viruses though inhibition of nuclear import of host and viral proteins.
Although it was previously tested in a Phase III clinical trial in Thailand in 2014-17 against DENV infection and found inefficacious with a single daily oral dosage, the authors of the paper believe that Ivermectin's nuclear transport inhibitory activity through IMPα/β1-mediated nuclear import of viral proteins may be effective against SARS-CoV-2 with an enhanced pharmacokinetic data driven dosing regimen.
Source (DOI): he FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro https://doi.org/10.1016/j.antiviral.2020.104787
Citation: : Caly, L., Druce, J.D., Catton, M.G., Jans, D.A., Wagstaff, K.M., The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Research, https://doi.org/10.1016/j.antiviral.2020.104787.
